Clinical Trial: A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Brief Summary: The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

Detailed Summary:
Sponsor: Kissei Pharmaceutical Co., Ltd.

Current Primary Outcome: Measure Adverse Events [ Time Frame: 52 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Serum phosphate concentrations [ Time Frame: 52 weeks ]

Original Secondary Outcome: Same as current

Information By: Kissei Pharmaceutical Co., Ltd.

Dates:
Date Received: April 12, 2013
Date Started:
Date Completion:
Last Updated: April 22, 2015
Last Verified: April 2015